RANCHO CORDOVA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that the Company has introduced a new line of veterinary point-of-care (POC) products under the Vantus brand. Unveiling of the first product, Res-Q60v ePRP, is taking place at this week's 54th Annual Convention of the American Association of Equine Practitioners (AAEP).
The initial product offering, Res-Q60v ePRP will be used for producing equine platelet-rich plasma (PRP) from 60 mL of blood. PRP is being used to treat ligament and tendon injuries in performance horses. The device enables veterinarians to prepare high quality PRP at the point-of-care in less than 15 minutes. The Company plans to introduce Res-Q60v eBMC, another equine product for producing high quality bone marrow concentrate, during calendar 2009. Many performance horses suffer orthopedic injuries and these biological products are emerging as a new means for the treatment to expedite healing of injured ligaments and tendons.
"We have been looking forward to launching the Res-Q60v ePRP at this prestigious equine industry event and commencing commercial sales in the early part of next year. The response among AAEP attendees was favorable and we look forward to participating in the veterinary market as an additional source of revenue for the company," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.
"We appreciate the collaborative efforts with the
"PRP delivers a high concentration of growth factors to damaged tissue
where they stimulate the healing cascade. PRP also has the potential to
minimize scarring and decrease the reinjury rate," noted Larry Galuppo, DMV,
Associate Professor and Chief of Equine Surgery in the Department of Surgical
and Radiological Sciences at the
"We are actively defining our marketing strategy to prioritize those opportunities that will enable ThermoGenesis to both meet its financial goals and to expand its leadership position in cell processing. The launch of the Res-Q(TM) technology is a device that addresses an existing and meaningful market opportunity," Plavan noted.
About ThermoGenesis Corp.
ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
-- The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress(TM) and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.
-- The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.
-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
ThermoGenesis Corp. Web site:http://www.thermogenesis.com Contact: Investor Relations +1-916-858-5107, or email@example.com
|SOURCE ThermoGenesis Corp.|
Copyright©2008 PR Newswire.
All rights reserved